Scott Harris

Scott Harris

Company: Altimmune

Job title: Chief Medical Officer


Weight Loss— The Preferred Treatment for NASH 9:00 am

• Bariatric and epidemiologic studies provide compelling evidence that weight loss is the preferred treatment option for NASH and its co-morbidities • GLP-1 based agents and dual agonists have achieved sufficient weight loss in clinical trials to drive potent reductions in liver fat reduction and NASH inflammation, but further evidence is needed to demonstrate meaningful…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.